BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $1.44, $0.61 better than the analyst estimate of $0.83. Revenue for the quarter came in at $825 million versus the consensus estimate of $760.37 million.

GUIDANCE:

BioMarin Pharma sees FY2025 EPS of $4.40-$4.55, versus the consensus of $4.16. BioMarin Pharma sees FY2025 revenue of $3.12-3.2 billion, versus the consensus of $3.14 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.